APO866 (FK866) (0.09-27 nM) induces dose-dependent cytotoxicity in 41 hematologic malignant cells including acute myeloid leukemia, acute lymphoblastic leukemia, mantle cell lymphoma, chronic lymphocytic leukemia, and T-cell lymphoma. APO866 (FK866) (0-10 nM) dose-dependently induces depletion of intracellular NAD and ATP contents and cell death in various hematologic cancer cells. APO866 (FK866) (10 nM) inhibits PBEF-induced secretion of MMP-3, CCL2, and CXCL8 in HFFF2 cells. APO866 administered intraperitoneally at dose of 20 mg/kg twice a day for 4 days, repeat weekly over 3 weeks, prevents and abrogats tumor growth in C.B.-17 SCID mice xenograft models of human AML, lymphoblastic lymphoma, and leukemia.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||Ethanol 50 mg/mL|
|Related Transferase Products|
Tunicamycin is a mixture of homologous nucleoside antibiotics that inhibits the UDP-HexNAc: polyprenol-P HexNAc-1-P family of enzymes.
Tolcapone is a selective, potent and reversible of catechol-O-methyl transferase (COMT) inhibitor with Ki of 30 nM.
PF-04620110 is an orally active, selective and potent diglyceride acyltransferase-1 (DGAT1) inhibitor with IC50 of 19 nM.
LB42708 is an orally active farnesyltransferase (FTase) inhibitor with IC50 of 0.8, 1.2, and 2.0 nM toward H-ras, N-ras, and K-ras, respectively.
GlcNAcstatin inhibits a bacterial O-GlcNAcase (bOGA) with a Ki of 4.6 pM, inhibits human O-GlcNAcase (hOGA) with Ki of 4.4 nM, exhibits 164-fold selectivity over HexA/B.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.